Astria Therapeutics is a biopharmaceutical company, and it's mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Astria's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema.